372 related articles for article (PubMed ID: 29673280)
1. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.
Lusa A; Carlson A
Lupus; 2018 Sep; 27(10):1723-1728. PubMed ID: 29673280
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.
Gudbrandsdottir S; Frederiksen H; Hasselbalch H
Platelets; 2012; 23(6):423-9. PubMed ID: 22185370
[TBL] [Abstract][Full Text] [Related]
3. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
[TBL] [Abstract][Full Text] [Related]
4. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
5. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
[No Abstract] [Full Text] [Related]
8. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
9. Moving towards a new era in the management of chronic immune thrombocytopenia.
Wadenvik H; Olsson B
Ann Hematol; 2010 Jul; 89 Suppl 1():87-93. PubMed ID: 20339846
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
PLoS One; 2018; 13(6):e0198504. PubMed ID: 29856837
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia.
Kuter DJ
Annu Rev Med; 2009; 60():193-206. PubMed ID: 19642221
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.
Poston JN; Gernsheimer TB
Int J Hematol; 2019 Aug; 110(2):255-259. PubMed ID: 30972617
[TBL] [Abstract][Full Text] [Related]
13. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
Zeng Y; Duan X; Xu J; Ni X
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD008235. PubMed ID: 21735426
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
16. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Atkinson K
Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
[TBL] [Abstract][Full Text] [Related]
17. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
[TBL] [Abstract][Full Text] [Related]
18. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
Cooper N; Scully M; Percy C; Nicolson PLR; Lowe G; Bagot CN; Thachil J; Grech H; Nokes T; Hill QA; Bradbury C; Talks K; Dutt T; Evans G; Pavord S; Wexler S; Charania A; Collington SJ; Ervin A; Ramscar N; Provan D
Br J Haematol; 2024 Jun; 204(6):2442-2452. PubMed ID: 38429869
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
20. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Kuter DJ
Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]